Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
FGFR1 amplification
Cancer:
Breast Cancer
Drug Class:
Aromatase inhibitor
Direction:
Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Clin Transl Oncol
Title:
CCND1 and FGFR1 gene amplifications are associated with reduced benefit from aromatase inhibitors in metastatic breast cancer
Published date:
09/02/2020
Excerpt:
Presence of CCND1 and/or FGFR1 amplification is associated with worse outcomes of AI therapy in patients with metastatic BC.
DOI:
10.1007/s12094-020-02481-w
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login